US FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukemia

April 3, 2018 AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for moxetumomab pasudotox, an...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news